Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: Structure-function analysis

Leukemia

Volumn 13, Issue 8, 1999, Pages 1243-1253

  DiGiuseppe, J A ^a   Weng, L J ^a   Yu, K H ^a   Fu, S ^a   Kastan, M B ^a   Samid, D ^b   Gore, S D ^a,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia; Cytostatic agents; Differentiation therapy; ML 1 cells; Myelodysplasia

Indexed keywords

ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; BUTYRIC ACID; CD11B ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOSTATIC AGENT; FATTY ACID; PHENYLACETIC ACID; PROTEIN P21; RETINOBLASTOMA PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MITOSIS INHIBITION; MYELOPOIESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION;

EID: 0032842703     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401471     Document Type: Article

References (57)

1. Steinman R, Hoffman B, Iro A, Guillouf C, Lieberman DA, El-Houseini ME. Induction of p21 (WAF1/CIP1) during differentiation. Oncogene 1994; 9: 3389-3396.
2. Warrell RP, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). New Engl J Med 1991; 324: 1385-1393.
3. Gore SD, Samid D, Weng L-J. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res 1997; 3: 1755-1762.
4. Brusilow SW, Danney M, Waber LJ, Batshaw M, Burton B, Levitsky L, Roth K, McKeethren C, Ward J. Treatment of episodic hyperammonemia in children with inborn errors of metabolism. New Engl J Med 1984; 310: 1630-1634.
5. Samid D, Yeh A, Prasanna P. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood 1992; 80: 1576-1581.
6. Samid D, Shack S, Sherman LT. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res 1992; 52: 1988-1992.
7. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
8. Imamura J, Miyoshi I, Koeffler HP. p53 in hematologic malignancies. Blood 1994; 84: 2412-2421.
9. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow: II. Normal B lymphocyte development. Blood 1987; 70: 1316-1324.
10. Kastan MB, Stone KD, Civin CI. Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells. Blood 1989; 74: 1517-1524.
11. Dolbeare F, Gratzner H, Pallavicini MG, Gray JW. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci USA 1983; 80: 5573-5577.
12. Dolbeare F, Kuo W-L, Beisker W, Vanderlaan M, Gray JW. Using monoclonal antibodies in bromodeoxyuridine-DNA analysis. Meth Cell Biol 1990; 33: 227-234.
13. Canman CE, Gilmer TM, Coutts SB, Kastan MB. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 1995; 9: 600-611.
14. Gore SD, Kastan MB, Goodman SN, Civin CI. Detection of minimal residual T cell acute lymphoblastic leukemia by flow cytometry. J Immunol Meth 1990; 132: 275-286.
15. Gore SD, Weng L, Burke PJ. Validation of flow cytometric determination of Ki67 expression as a measure of growth factor response in acute myelogenous leukemia. Exp Hematol 1993; 21: 1702-1708.
16. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420
17. Gore SD, Weng L, Jones RJ, Cowan K, Zilcha M, Piantadosi S, Burke PJ. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia. Clin Cancer Res 1995; 1: 295-303.
18. WAF1/CIP1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-684.
19. 1 arrest in human cancer cells. Cancer Res 1995; 55: 5187-5190.
20. Hirami T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86: 841-854.
21. Zhang W, Grasso L, McClain CD, Gambel AM, Cha Y, Travali S, Deisseroth AB, Mercer WE. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth and arrest accompanying monocyte/macrophage differentiation. Cancer Res 1995; 55: 668-674.
22. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1994; 9: 3397-3406.
23. WAF1/CIP1/SD11 in differentiating human leukemia cells. J Clin Invest 1995; 95: 973-979.
24. Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 1993; 82: 15-21.
25. Gorczyca W, Gong J, Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 1993; 53: 1945-1951.
26. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry 1992; 13: 795-808.
27. Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, Ervin T, Kufe D, Rifkind RA, Marks PA. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 1992; 80: 2604-2609.
28. Rowinsky EK, Donehower RC, Spivak JL, Burke PJ, Griffin CA, Jones RJ. Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors. J Natl Can Inst 1990; 82: 7926-1931.
29. Koeffler HP, Hirji K, Itri L, and the Southern California Leukemia Group. 1,25-dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 1985; 69: 1399-1407.
30. Samid D, Shack S, Myers CE. Selective growth arrest and phenyotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 1993; 91: 2288-2295.
31. Samid D, Ram Z, Hudgins WR, Shack S, Liu L, Walbridge S, Oldfield EH, Myers CE. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res 1994; 54: 891-895.
32. Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, Samid D, Myers CE. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 1994; 54: 1690-1694.
33. Soddu S, Blandino G, Citro G, Scardigli R, Piaggio G, Ferber A, Calabretta B, Sacchi A. Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood 1994; 83: 2230-2237.
34. Soddu S, Blandino G, Scardigli R, Coen S, Marchetti A, Rizzo MG, Bossi G, Cimino L, Crescenzi M, Sacchi A. Interference with p53 protein inhibits hematopoietic and muscle differentiation. J Cell Biol 1996; 134: 193-204.
35. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ, Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-597.
36. Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 1993; 82: 1092-1096.
37. Horiguchi-Yamada J, Yamada H. Differing responses of G2-related genes during differentiation of HL60 cells induced by TPA or DMSO. Mol Cell Biochem 1993; 119: 29-34.
38. Haas R, Gunji H, Datta R, Kharbanda S, Hartmann A, Weichselbaum R, Kufe D. Differentiation and retrodifferentiation of human myeloid leukemia cells is associated with reversible induction of cell cycle-regulatory genes. Cancer Res 1992; 52: 1445-1450.
39. Vandewalle B, Wattez N, Lefebvre J. Effects of vitamin D3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: possible implication of intracellular calcium. Cancer Lett 1995; 97:99-106.
40. Hunakova L, Sedlak J, Klobusicka M, Duraj J, Chorvath B. Tyrosine kinase inhibitor-induced differentiation of K562 cells: alterations of cell cycle and cell surface phenotype. Cancer Lett 1994; 81: 81-87.
41. Richon VM, Rifkind RA, Marks PA. Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells. Cell Growth Diff 1992; 3: 416-20.
42. Marks PA, Richon VM, Kiyokawa H, Rifkind RA. Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process. Proc Natl Acad Sci USA 1994; 91: 10251-10254.
43. Richon VM, Russo P, Venta-Perez G, Cordon-Cardo C, Rifkind RA, Marks PA. Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells. Cancer Res 1997; 57: 2789-2798.
44. Richon VM, Rifkind RA, Marks PA. Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells. Cell Growth Diff 1992; 3: 413-420.
45. Zhuo S, Fan S, Huang S, Kaufman S. Study of the role of retinoblastoma protein in terminal differentiation of murine erythroleukemia. Proc Natl Acad Sci USA 1995; 92:4234-4238.
46. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996; 93: 5705-5708.
47. Daniel P, Brazier M, Cerutti I, Pieri F, Tardivel I, Desmet G, Baillet J, Chany C. Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts. Clin Chim Acta 1989; 181: 255-264.
48. Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickie cell anemia by oral sodium phenylbutyrate. Blood 1994; 84: 339-343.
49. Brusilow SW. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res 1991; 29: 147-150.
50. 2-mediated apoptosis of human colorectal carcinoma cells. Mol Cell Biol 1996; 16: 6654-6660.
51. Munker R, Kobayashi T, Elstner E, Norman AW, Uskokovic M, Zhang W, Andreeff M, Koeffler HP. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 1996; 88: 2201-2209.
52. Pineau T, Hudgins WR, Liu L, Chen L-C, Sher T, Gonzales FJ, Samid D. Activation of a peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharm 1996; 52: 659-667.
53. Lea MA, Tulsyan N. Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase. Anticancer Res 1995; 15: 879-883.
54. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T. Histone deacetylase inhibitor activates the WAF1/CIP1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997; 241: 142-150.
55. Brusilow SW, Finkelstien J. Restoration of nitrogen homeostasis in a man with ornithine transcarbamylase deficiency. Metabolism 1993; 42: 1336-1339.
56. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 1995; 85: 43-49.
57. Breitman TR, He R. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. Cancer Res 1990; 60: 6268-6273.